After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities.
Stocks Info
As a NYSE listed company, RCUS falls under the Healthcare sector while operating within the Biotechnology industry segment. The current market capitalization of Arcus Biosciences Inc is $2.72B. A total of 4.5 million shares were traded on the day, compared to an average of 1.77M shares.
In the most recent transaction, Tang Carolyn C. sold 7,658 shares of RCUS for 21.88 per share on Dec 16 ’25. After the transaction, the General Counsel now owns 131,544 company shares. In a previous transaction on Dec 17 ’25, Tang Carolyn C. sold 6,810 shares at 22.16 per share. RCUS shares that General Counsel owns now total 124,734.
Among the insiders who sold shares, Markus Richard disposed of 5,052 shares on Dec 16 ’25 at a per-share price of $21.88. This resulted in the Chief Medical Officer holding 70,141 shares of RCUS after the transaction. In another insider transaction, Markus Richard sold 4,494 shares at $22.16 per share on Dec 17 ’25. Company shares held by the Chief Medical Officer now total 65,647.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, RCUS has a high of $26.40 and a low of $6.50.
As of this writing, RCUS has an earnings estimate of -$1.08 per share for the current quarter. EPS was calculated based on a consensus of 4.0 estimates, with a high estimate of -$1.0 per share and a lower estimate of -$1.11. The company reported an EPS of -$1.03 in the last quarter
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. RCUS’s latest balance sheet shows that the firm has $499.00M in Cash & Short Term Investments as of fiscal 2021. There were $116.89M in debt and $166.00M in liabilities at the time. Its Book Value Per Share was $4.07, while its Total Shareholder’s Equity was $842.00M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for RCUS is Buy with a score of 4.54.
